The pharmacokinetics of teicoplanin were determined after multiple 30-min intravenous infusions of 10 to 15 mg/kg every 12 to 24 h in 11 intravenous drug abuse (IVDA) patients being treated for bacterial endocarditis. Multiple serum samples were obtained over 7 to 14 days. Twenty-four-hour urine collections were obtained on days 1 and 5. Serum concentration-time data were analyzed by using multiple-dose pharmacokinetic analysis (NONLIN84). Results were compared with pharmacokinetic parameters derived from previous studies in normal healthy volunteers following multiple intravenous infusions of teicoplanin (3 to 6 mg/kg/day). Total and renal clearances of teicoplanin in IVDA patients were found to be significantly greater and more highly variable than those observed previously in normal healthy volunteers. As a result, predicted steady-state trough concentrations in serum may vary up to fivefold. The mechanism responsible for this variation appears to be related to the glomerular filtration rate. In IVDA patients, individualized teicoplanin dosage may be required in the treatment of bacterial endocarditis.
Teicoplanin is an investigational glycopeptide which is chemically related to vancomycin. Like vancomycin, it is active against gram-positive aerobic and anaerobic bacteria, including methicillin-resistant staphylococci (6, 8, 9, 21, (24) (25) (26) . The in vivo activity of teicoplanin for serious staphylococcal infections has been established in experimental animal models (5, 10, 23) . Clinical evaluations of teicoplanin for serious infections caused by gram-positive bacteria have demonstrated the potential efficacy of the drug, although clinical failures with low-dosage regimens have contributed to doubts regarding its ultimate utility (4, 13, 17, 28) . Unlike vancomycin, teicoplanin can be administered intramuscularly, and it has a long terminal elimination half-life which permits extended dosing intervals. Furthermore, teicoplanin may have a lower toxicity profile (2, 4, 26) .
In a preliminary comparative efficacy trial of teicoplanin versus vancomycin for intravenous drug abuse (IVDA)-associated bacterial endocarditis at Detroit Receiving Hospital, teicoplanin concentrations in serum were consistently lower than expected based on the pharmacokinetics of teicoplanin in normal healthy volunteers (Fig. 1) . As a result of this observation, we determined the pharmacokinetics of teicoplanin in IVDA-associated bacterial endocarditis, in order to explore the possible mechanisms responsible for these findings.
(The results of this study were presented in part at the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy [20] .) MATERIALS Analytical methods. Serum and urine were analyzed for teicoplanin by a bioassay (Bacillus subtilis ATCC 6633) (7). Serum containing beta-lactams (subject 11) was pretreated with the appropriate P-lactamase (15) . For urine, samples were diluted 1:10 in 0.1 M phosphate buffer (pH 7.4) supplemented with 1% normal human serum (Flow Laboratories, McLean, Va.). Within-and between-run coefficients of variation were less than 10% for the serum assay (control samples, 38 and 0.19 mg/liter) and <15% for the urine assay (control samples, 240 and 64 mg/liter). The lower limits of quantitation for teicoplanin in serum and urine were 0.19 and 3.0 mg/liter, respectively. Pharmacokinetic analysis. By using NONLIN84 (22), serum concentration-time data were fit to a three-and fourexponential function as described by the following equation:
where k is the number of doses administered; n is the number of exponentials (three or four) necessary to characterize the serum concentration-time profile following a single dose; Dj is the size of the jth dose (mg/kg); D1 is the size of the initial dose (mg/kg); Ci is the ith coefficient which corresponds to the initial dose; Li is the ith exponent; TIj is the duration of thejth infusion; bj is a second independent variable equal to tj during the jth infusion and equal to TIj after the jth infusion; and tj is the time after the start of the jth infusion. Initial parameter estimates were obtained from a previous study conducted in normal healthy volunteers (18) . Various weightings of the observed concentrations in serum were used in the data analysis. Decisions on the appropriate weighting and the number of exponentials required to characterize the serum concentration-time profile were based on visual inspection of the randomness of scatter of the observed data about the fitted line. If both models resulted in random residuals, the reduction in the sum of weighted squared residuals was used to decide on the appropriate model (3, 11) . CLR was obtained as the ratio of the amount of teicoplanin recovered in urine to the area under the predicted serum concentration-time profile (determined over the same time). The area under the predicted serum concentration-time profile was determined by the linear trapezoidal rule method (by using concentrations predicted every 0.1 h). Volumes of distribution, total clearance, terminal elimination half-life, and predicted steady-state serum concentra- tion-time profiles were obtained (from the coefficients and exponents) by using standard equations (12, 14, 27) .
Statistical analysis. The relationship between CLCR and/or albumin to the teicoplanin CLR was determined by a generalized maximum likelihood regression procedure (29) . The significance of each parameter was determined from the parameter estimate, standard error, and associated degrees of freedom by using a t distribution. Differences in the pharmacokinetic parameters were compared with values obtained in normal healthy volunteer subjects by using a two-sided Wilcoxon rank sum test. Statistical significance was defined as P < 0.05. Data are presented as median (range), unless indicated otherwise.
RESULTS
Twenty-nine patients were enrolled into the study. Of these, 11 patients (6 males) fulfilled the sampling criteria (at least 7 days of sampling which resulted in a mean of 46.8 and a range of 38 to 59 samples per patient) for inclusion in the overall pharmacokinetic analysis. Of those 11 patients, complete urine collection data were not available for 1 patient. Three additional patients for whom urine collections were complete (dose 1) but who did not complete therapy beyond the loading dose procedure were included in the teicoplanin CLR analysis only. Demographics, including the type of infection and pathogen for patients included in the complete analysis, are listed in Table 1 . In this group of patients, serum albumin levels tended to be low (mean, 2.7 mg/dl; range, 1.5 to 3.7 mg/dl) and CLCR varied widely (mean, 115.3 ml/min; range, 50.0 to 186 ml/min). Good agreement between observed and predicted serum concentration-time profiles was obtained for each individual (Fig. 2) . Total clearance and CLR of teicoplanin were found to be significantly higher and more variable in IVDA patients than in normal healthy volunteers (Tables 2 and 3 ). As a result of the higher clearance without a significant change in the volume of distribution, the terminal elimination half-life of teicoplanin in IVDA patients was significantly decreased. In addition, predicted steady-state concentrations of teicoplanin in serum were considerably lower in IVDA patients than they were in normal subjects (Table 4) . A significant correlation (R2 = 0.95) (Fig. 3) was found between teicoplanin CLR and CLCR in IVDA patients. Use of serum albumin concentrations as an indicator of protein binding did not significantly explain any of the variation in CLR of teicoplanin (R2 = 0.022). Furthermore, the inclusion of serum albumin with CLCR did not further improve the correlation (R2 = 0.903).
DISCUSSION
Treatment failures associated with lower than expected serum teicoplanin concentrations in IVDA patients treated for bacterial endocarditis prompted a careful examination of the pharmacokinetics of teicoplanin in this patient population. Although treatment failures and variable serum teicoplanin concentrations were reported during early clinical trials, no investigation has been conducted to determine the possible mechanism(s) for these findings (4, 13) . The reasons for these findings are unclear. However, there have been several hypotheses. These include the possibility that the impaired efficacy of teicoplanin in staphylococcal infections might result from the high degree of teicoplanin protein binding (consequently, a low free concentration in serum, presumably, and at the site of infection), inadequate loading and maintenance dosage regimens, and patient-specific variability related to the type of infection (2, 4) . This investigation specifically studied IVDA patients who were septic and who had a presumed diagnosis of infective endocarditis. Our earlier data indicated that, in this population, expected serum teicoplanin concentrations were not achieved (based on the pharmacokinetics of teicoplanin in normal healthy volunteers). The finding of a significantly higher CLR of teicoplanin in IVDA patients supports these earlier observations of lower concentrations in serum. In previous studies (18) , the CLR of teicoplanin was consistently related to the glomerular filtration rate (corrected for protein binding). In our study, the higher CLR of teicoplanin appears to be primarily related to a higher glomerular filtration rate. A previous study (1) pharmacokinetic parameter were observed between IVDA patients and normal healthy volunteers.
There have been two published reports of altered antibiotic pharmacokinetics in IVDA patients. In a study by King et al. (16) , the pharmacokinetics of aminoglycosides were determined in 18 hospitalized IVDA patients receiving gentamicin or tobramycin for severe infections. Rapid aminoglycoside elimination requiring dosages greater than 5 mg/ kg/day was reported in 12 of the 18 patients. Although several variables (i.e., younger age, greater CLCR, and increased volume of distribution) were noted to be significant in this group of patients, they were unreliable indicators of rapid aminoglycoside elimination when evaluated by regression analysis. The authors concluded that IVDA patients represent a clinically unpredictable patient population subgroup which requires aggressive and individualized aminoglycoside dosing based on monitoring of the drug concentration in serum. Rybak et al. (19) evaluated the pharmacokinetics of vancomycin in burn and IVDA patients. While the mean CLR of vancomycin was not statistically different in IVDA patients, it was found to be 31% higher than that in control patients. The mechanism of enhanced clearance appeared to be both increased filtration and increased active secretion. Of interest in the present study, the teicoplanin CLR was significantly correlated with the teicoplanin CLCR. It is possible that the disease states in our patients may have been a factor which led to a higher glomerular filtration rate and, consequently, higher teicoplanin clearances. However, since our patient population was small and the subjects had similar diagnoses (presumed endocarditis), it is difficult to determine whether the degree of the disease state contributes to the unusually high glomerular filtration rate and the high teicoplanin CLR. It has been noted previously that patients with staphylococcal bacteremia have had variable concentrations of teicoplanin in serum. However, these observations have also been made in small patient populations with dosing and sample collection methods which have differed markedly between studies (2, 13).
In conclusion, the total clearance of teicoplanin in IVDA patients (being treated for endocarditis) may be highly variable and may result in a wide range of concentrations of teicoplanin in serum. The estimated CLCR and low serum albumin may not be adequate in predicting those patients who require a dosage adjustment in order to achieve the desired concentrations of teicoplanin in serum. In IVDA patients, individualized teicoplanin dosage regimens based on monitoring of the concentration in serum is likely to be beneficial in the treatment of bacterial endocarditis.
